FR22C1025I1 - Analogues de la compstatine à longue durée d'action et compositions et méthodes associées - Google Patents

Analogues de la compstatine à longue durée d'action et compositions et méthodes associées

Info

Publication number
FR22C1025I1
FR22C1025I1 FR22C1025C FR22C1025C FR22C1025I1 FR 22C1025 I1 FR22C1025 I1 FR 22C1025I1 FR 22C1025 C FR22C1025 C FR 22C1025C FR 22C1025 C FR22C1025 C FR 22C1025C FR 22C1025 I1 FR22C1025 I1 FR 22C1025I1
Authority
FR
France
Prior art keywords
methods
long
related compositions
compstatin analogs
acting compstatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1025C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apellis Pharmaceuticals Inc
Original Assignee
Apellis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apellis Pharmaceuticals Inc filed Critical Apellis Pharmaceuticals Inc
Publication of FR22C1025I1 publication Critical patent/FR22C1025I1/fr
Application granted granted Critical
Publication of FR22C1025I2 publication Critical patent/FR22C1025I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
FR22C1025C 2012-11-15 2022-06-08 Analogues de la compstatine à longue durée d'action et compositions et méthodes associées Active FR22C1025I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261727094P 2012-11-15 2012-11-15
PCT/US2013/070417 WO2014078731A2 (fr) 2012-11-15 2013-11-15 Analogues de la compstatine réactifs aux cellules, à longue durée d'action ou ciblés et compositions et méthodes associées
EP13854990.2A EP2920201B1 (fr) 2012-11-15 2013-11-15 Analogues de la compstatine à longue durée d'action et compositions et méthodes associées

Publications (2)

Publication Number Publication Date
FR22C1025I1 true FR22C1025I1 (fr) 2022-07-22
FR22C1025I2 FR22C1025I2 (fr) 2023-11-24

Family

ID=50731833

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1025C Active FR22C1025I2 (fr) 2012-11-15 2022-06-08 Analogues de la compstatine à longue durée d'action et compositions et méthodes associées

Country Status (24)

Country Link
US (4) US10035822B2 (fr)
EP (3) EP2920201B1 (fr)
JP (4) JP2016505527A (fr)
CN (2) CN105051057B (fr)
AU (4) AU2013344462B2 (fr)
BR (1) BR112015011244B1 (fr)
CA (1) CA2891673A1 (fr)
CY (1) CY1124474T1 (fr)
DK (2) DK2920201T3 (fr)
ES (2) ES2780674T3 (fr)
FR (1) FR22C1025I2 (fr)
HK (2) HK1215445A1 (fr)
HR (1) HRP20211342T2 (fr)
HU (2) HUE055564T2 (fr)
IL (2) IL238852A0 (fr)
LT (2) LT3660033T (fr)
MX (2) MX366404B (fr)
NO (1) NO2022017I1 (fr)
PL (2) PL2920201T3 (fr)
PT (2) PT3660033T (fr)
RS (1) RS62243B9 (fr)
RU (1) RU2705215C2 (fr)
SI (1) SI3660033T1 (fr)
WO (1) WO2014078731A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
EP4105224A1 (fr) 2011-05-11 2022-12-21 Apellis Pharmaceuticals, Inc. Analogues de la compstatine à longue durée d'action et leurs utilisations
PT3660033T (pt) 2012-11-15 2021-07-06 Apellis Pharmaceuticals Inc Análogos de compstatina de longa ação e composições e métodos relacionados
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
WO2017035405A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés amino pour le traitement de troubles immunitaires et inflammatoires
WO2017035401A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés amide pour le traitement de troubles immunitaires et inflammatoires
CN117503905A (zh) 2015-10-07 2024-02-06 阿佩利斯制药有限公司 给药方案
CN110249053A (zh) 2016-10-17 2019-09-17 阿佩利斯制药有限公司 用于c3抑制的组合疗法
EP3985002A1 (fr) 2017-03-01 2022-04-20 Achillion Pharmaceuticals, Inc. Composés pharmaceutiques aryle, hétéroaryles et hétérocycliques pour le traitement de troubles médicaux
WO2018160891A1 (fr) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Composés pharmaceutiques destinés au traitement de troubles médicaux
CA3059304A1 (fr) * 2017-04-07 2018-10-11 Apellis Pharmaceuticals, Inc. Schemas posologiques et compositions et procedes associes
CN109701030A (zh) * 2017-10-26 2019-05-03 湖南华腾制药有限公司 聚乙二醇化小分子药物的制备方法
AU2018386304B2 (en) * 2017-12-15 2023-12-07 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
JP7423070B2 (ja) 2018-04-06 2024-01-29 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 増加した溶解度および改善された薬物動態特性を有するコンプスタチンアナログ
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
EP3847174A4 (fr) 2018-09-06 2022-06-15 Achillion Pharmaceuticals, Inc. Formes morphiques d'inhibiteurs du facteur d du complément
WO2020069024A1 (fr) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Formes morphiques d'inhibiteurs du facteur d du complément
WO2020109343A1 (fr) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Polythérapie pour le traitement de la dégénérescence maculaire
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
CN110244053B (zh) * 2019-05-09 2022-03-11 北京大学第三医院（北京大学第三临床医学院） 用于诊断狼疮肾炎并肺动脉高压疾病的分子标志物及其用途
EP3996744A4 (fr) * 2019-07-05 2023-07-12 Apellis Pharmaceuticals, Inc. Thérapie par vecteurs viraux
US20220280598A1 (en) * 2019-07-18 2022-09-08 Apellis Pharmaceuticals, Inc. Complement inhibitor dosing regimens
CN111235264B (zh) * 2020-02-20 2023-05-16 圣湘生物科技股份有限公司 检测人tpmt基因和nudt15基因多态性的组合物、试剂盒及方法
CN111265651A (zh) * 2020-02-29 2020-06-12 华中科技大学同济医学院附属同济医院 补体c3抑制剂cp40-kk在制备防治肺动脉高压病药物中的应用
EP4132547A1 (fr) * 2020-04-06 2023-02-15 The Trustees of Indiana University Thérapie alcaline de l'épithélium respiratoire pour traiter une infection respiratoire virale

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2295746A1 (fr) 1974-12-23 1976-07-23 Francaise Coop Pharma Nouveaux derives du tryptophane a activite nerveuse centrale renforcee
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IT1179866B (it) 1984-12-12 1987-09-16 Rotta Research Lab Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
US4576750A (en) 1985-04-22 1986-03-18 Merck & Co., Inc. Tryptophan derivative
US5157110A (en) 1988-08-20 1992-10-20 The Government Of The United States Of America Synthetic, anti-complement protein
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
IL95942A0 (en) 1989-10-13 1991-07-18 Syntex Inc Collagen-containing ophthalmic formulation
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
EP1413587A2 (fr) 1991-05-03 2004-04-28 Washington University Régulateur modifié du système de complément
US5492135A (en) 1992-09-09 1996-02-20 Devore; Dale P. Collagen modulators for use in photoablation excimer laser keratectomy
US5482135A (en) 1993-06-29 1996-01-09 Deere & Company Combined hydraulic reservoir and vehicle axle
WO1995003009A1 (fr) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Methode de traitement de la degenerescence maculaire
WO1995003807A1 (fr) 1993-07-27 1995-02-09 The University Of Sydney Traitement de la degenerescence maculaire due au vieillissement
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5776970A (en) 1994-04-28 1998-07-07 Yeda Research And Development Co. Ltd. Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
JPH08280800A (ja) 1995-04-12 1996-10-29 Nissho Corp ２液注射用プレフィルドシリンジ
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6129761A (en) 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
CA2248772C (fr) 1996-03-13 2007-06-12 John D. Lambris Nouveaux peptides inhibant l'activation du complement
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
AU3487697A (en) 1996-06-14 1998-01-07 Johns Hopkins University School Of Medicine, The Use of chimeric vaccinia virus complement control proteins to inhibit complement
JPH1087700A (ja) 1996-06-17 1998-04-07 Smithkline Beecham Corp Ｃ３ａ受容体およびＣ３ａを用いる治療およびスクリーニング方法
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
WO1998046270A2 (fr) 1997-04-11 1998-10-22 Advanced Medicine, Inc. Molecules presentant une pluralite de groupes fonctionnels actifs
AU6957098A (en) 1997-04-11 1998-11-11 Advanced Medicine, Inc. Polyvalent presenter combinatorial libraries and their uses
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
US6169057B1 (en) 1997-09-04 2001-01-02 The Regents Of The University Of California Use of tryptophan and analogs as plant growth regulators
WO1999013899A1 (fr) 1997-09-17 1999-03-25 Trustees Of The University Of Pennsylvania Peptides et peptidomimetiques inhibant l'activation du complement
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
JPH11197234A (ja) 1998-01-09 1999-07-27 Koken Co Ltd 眼科用コラーゲンゲル成形物
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
WO1999044625A1 (fr) 1998-03-03 1999-09-10 John Hopkins University Inhibiteur d'enzymes de complement, derive du virus de la variole (spice), proteines liees au spice et methode d'inhibition de l'activation du complement
WO1999052539A1 (fr) 1998-04-10 1999-10-21 Mayo Foundation For Medical Education And Research Neo-tryptophane
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US7084106B1 (en) 1999-01-19 2006-08-01 University Of Louisville Research Foundation, Inc. Application of a viral complement inhibitory protein in the treatment and diagnosis of Alzheimer's Disease
BR0008787A (pt) 1999-02-12 2001-11-06 Collagenesis Inc Sistema à base de colágeno injetável para aplicação de células ou agentes terapêuticos
US7108982B1 (en) 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
US20020102581A1 (en) 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
ATE303816T1 (de) 1999-05-25 2005-09-15 King Faisal Specialist Hospita Neue therapeutische verwendung eines eine virale ansteckung modulierendes protein zur verhinderung von abstossung von fremdtransplantaten
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
GB9930659D0 (en) 1999-12-24 2000-02-16 Bio Discovery Ltd Inhibitors of complement activation
US20050020525A1 (en) 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
AU6110301A (en) 2000-04-29 2001-11-12 Univ Iowa Res Found Diagnostics and therapeutics for macular degeneration-related disorders
US6692759B1 (en) 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
WO2002011793A1 (fr) 2000-08-08 2002-02-14 Medical Information Services, Inc. Seringue pour preparation de necessaire d'injection, valve coulissante intermediaire pour seringues et preparation de necessaire d'injection
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
ES2483991T3 (es) 2000-10-10 2014-08-08 Genentech, Inc. Anticuerpos contra C5 que inhibe la activación de las células endoteliales de tipo II
DK2813582T3 (en) 2000-12-01 2017-07-31 Max-Planck-Gesellschaft Zur Förderung Der Wss E V Small RNA molecules that mediate RNA interference
ATE359762T1 (de) 2001-01-09 2007-05-15 Microchips Inc Flexible mikrochip-vorrichtungen zur ophthalmologischen und anderen applikation
US20050054596A1 (en) 2001-11-30 2005-03-10 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
TWI260327B (en) 2001-11-09 2006-08-21 Osi Eyetech Inc Pharmaceutical compositions for treating ocular neovascular diseases
AU2002365603A1 (en) 2001-12-04 2003-06-17 Nanospectra Biosciences, Inc. Treatment of angiogenesis disorders using targeted nanoparticles
DE60315949T2 (de) * 2002-01-16 2008-06-12 Biocompatibles Uk Ltd., Farnham Polymerkonjugate
US7261876B2 (en) * 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
AUPS160602A0 (en) 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
US20040092470A1 (en) 2002-06-18 2004-05-13 Leonard Sherry A. Dry powder oligonucleotide formualtion, preparation and its uses
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
JP3976635B2 (ja) 2002-08-05 2007-09-19 久光製薬株式会社 キット製剤用注射器、注射器型キット製剤用中間摺動弁、及び、注射器型キット製剤、並びにｘ線造影剤キット製剤
WO2004026328A1 (fr) 2002-09-20 2004-04-01 The Trustees Of The University Of Pennsylvania Analogues de compstatine à activité améliorée
US20060251621A1 (en) 2002-09-27 2006-11-09 Campochiaro Peter A Ocular gene therapy
WO2004037310A2 (fr) 2002-10-21 2004-05-06 Allvivo, Inc. Revetement de surface comprenant un compose bioactif
WO2004041160A2 (fr) 2002-10-30 2004-05-21 University Of Kentucky Research Foundation Procedes et cobaye animal d'analyse de la degenerescence maculaire liee a l'age
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
JP2006518750A (ja) 2003-02-21 2006-08-17 リクスホスピタレット−ラジウムホスピタレット・ホーエフ 胎便吸引症候群の治療のための方法および組成物
EP1601377A4 (fr) 2003-02-21 2009-07-15 Genentech Inc Procedes de traitement et de prevention des lesions tissulaires associees aux blessures par reperfusion ischemique
US20050255144A1 (en) 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
WO2005023296A1 (fr) 2003-09-05 2005-03-17 University Of Louisville Research Foundation, Inc. Traitement de maladies rhumatismales
CA2579635A1 (fr) 2003-09-10 2005-03-17 Baxter International Inc. Peptides permettant d'inhiber l'activation du complement
ES2432112T3 (es) 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados
PT1727567E (pt) 2004-02-12 2013-10-14 Archemix Llc Terapêuticas com aptâmeros úteis no tratamento de desordens relacionadas com o complemento
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
WO2005110374A1 (fr) 2004-04-30 2005-11-24 Allergan, Inc. Systemes de distribution de medicaments intraoculaires contenant un agent therapeutique, une cyclodextrine et un composant polymere
US20070142339A1 (en) 2004-05-10 2007-06-21 Novacea, Inc. Prevention of arterial restenosis with active vitamin d compounds
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
JP2008512350A (ja) 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
WO2006042252A2 (fr) 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Proteines regulatrices du complement viral pour troubles de la vue
US8043609B2 (en) 2004-10-08 2011-10-25 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
KR101290621B1 (ko) 2004-11-18 2013-07-29 더 락커펠러 유니버시티 안질환 치료용 방법 및 조성물
NZ608860A (en) 2005-02-14 2014-10-31 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
EP1861114B1 (fr) 2005-03-11 2011-02-02 Potentia Pharmaceuticals, Inc. Compositions renfermant des modulateurs du recepteur lié a la protéine g et destinees au traitement de la degenerescence maculaire
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
CA2625206C (fr) 2005-10-08 2021-12-07 Potentia Pharmaceuticals, Inc. Compstatine et analogues de celle-ci pour des troubles de la vue
WO2007047626A1 (fr) 2005-10-14 2007-04-26 Alcon, Inc. Traitement de combinaison comprenant de l'acetate d'anecortave et du bevacizumab ou du ranibizumab pour une angiogenese oculaire pathologique
CA2624393C (fr) 2005-11-04 2016-01-05 Genentech, Inc. Utilisation d'inhibiteurs de la voie du complement pour traiter des maladies oculaires
DK1960422T3 (da) 2005-11-28 2012-08-13 Univ Pennsylvania Meget virksomme compstatin-analoger
CN101346473A (zh) 2005-12-22 2009-01-14 爱尔康研究有限公司 用于在具有补体因子h的风险变体的患者中预防和治疗年龄相关性黄斑变性的c3-转化酶抑制剂
US20070196367A1 (en) 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
JP5313867B2 (ja) 2006-03-30 2013-10-09 ドライス ファーマシューティカルズ，インコーポレイティド カンプトテシン−細胞透過性ペプチド複合体及びそれを含む医薬組成物
ES2545775T3 (es) 2007-02-05 2015-09-15 Apellis Pharmaceuticals, Inc. Análogos de compstatina para uso en el tratamiento de afecciones inflamatorias del sistema respiratorio
WO2008106186A2 (fr) 2007-02-28 2008-09-04 Serina Therapeutics, Inc. Polyoxazolines activées et composition comprenant celles-ci
KR101470679B1 (ko) * 2007-07-19 2014-12-08 올엑셀, 인크. 항암제로서의 자기 조립형 양친매성 중합체
WO2009015087A2 (fr) 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions et procédés de traitement d'un traumatisme
WO2009043027A2 (fr) 2007-09-27 2009-04-02 Serina Therapeutics, Inc. Formes tentaculaires de polyoxazoline activée et leurs procédés de synthèse
KR20150080007A (ko) 2007-10-02 2015-07-08 포텐시아 팔마큐티칼스, 인크. 겔로부터 콤스타틴 유사체의 지속적 운반
EP2669313B1 (fr) 2008-01-11 2016-03-23 Serina Therapeutics, Inc. Formes multifonctionnelles de copolymères de polyoxazoline et compositions médicamenteuses les contenant
US8521273B2 (en) 2008-01-29 2013-08-27 Gilbert H. KLIMAN Drug delivery devices, kits and methods therefor
WO2009121065A2 (fr) 2008-03-28 2009-10-01 Apellis Ag Modulation et réplétion/amélioration du système complémentaire dans le traitement des traumatismes
EP2310440A4 (fr) 2008-07-10 2013-06-05 Serina Therapeutics Inc Polyoxazolines avec groupes terminaux inertes, polyoxazolines préparées à partir de groupes initiateurs protégés, et composés en rapport
EP2424557B1 (fr) 2009-05-01 2017-10-25 The Trustees Of The University Of Pennsylvania Compstatine modifiée avec squelette peptidique et modifications c-terminales
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
US20130041134A1 (en) * 2009-11-05 2013-02-14 Sangart ,Inc. Methods for preparing polyethylene glycol maleimide using n-(2-hydroxyethyl) maleimide as a starting material
EP2338520A1 (fr) 2009-12-21 2011-06-29 Ludwig Maximilians Universität Conjugué doté d'un liguant de recherche de cible et son utilisation
US8625635B2 (en) 2010-04-26 2014-01-07 Cleversafe, Inc. Dispersed storage network frame protocol header
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
WO2012006599A2 (fr) 2010-07-09 2012-01-12 Apellis Pharmaceuticals, Inc. Analogues de compstatine pour le traitement de la rhinosinusite et de la polypose nasale
US20140113874A1 (en) 2010-09-23 2014-04-24 The Trustees Of The University Of Pennsylvania Modified Compstatin With Improved Stability And Binding Properties
EP4105224A1 (fr) 2011-05-11 2022-12-21 Apellis Pharmaceuticals, Inc. Analogues de la compstatine à longue durée d'action et leurs utilisations
CA2840270C (fr) 2011-06-22 2023-09-26 Apellis Pharmaceuticals, Inc. Methodes de traitement de troubles chroniques au moyen d'inhibiteurs de complement
CN103987725B (zh) 2011-09-07 2019-04-16 宾夕法尼亚州大学理事会 具有改善的药代动力学性质的坎普他汀类似物
WO2014028861A1 (fr) 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Détection de drusen à risque élevé
WO2014078734A2 (fr) 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Analogues de la compstatine réactifs aux cellules, à longue durée d'action ou ciblés et compositions et méthodes associées
PT3660033T (pt) * 2012-11-15 2021-07-06 Apellis Pharmaceuticals Inc Análogos de compstatina de longa ação e composições e métodos relacionados
WO2014100407A1 (fr) 2012-12-19 2014-06-26 The Regents Of The University Of California Analogues de la compstatine
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9566459B2 (en) 2013-07-16 2017-02-14 Beijing Mechanical Equipment Institute Fire engine suitable for fire-fighting in high-rise and super high-rise buildings
US9806963B2 (en) 2013-10-18 2017-10-31 Cellco Partnership Feature activation on device
CN117503905A (zh) * 2015-10-07 2024-02-06 阿佩利斯制药有限公司 给药方案
CA3059304A1 (fr) * 2017-04-07 2018-10-11 Apellis Pharmaceuticals, Inc. Schemas posologiques et compositions et procedes associes

Also Published As

Publication number Publication date
CN110882376A (zh) 2020-03-17
ES2879430T3 (es) 2021-11-22
EP2920201A2 (fr) 2015-09-23
NO2022017I1 (no) 2022-05-25
JP2022120193A (ja) 2022-08-17
CY1124474T1 (el) 2022-07-22
US11292815B2 (en) 2022-04-05
ES2780674T3 (es) 2020-08-26
RS62243B1 (sr) 2021-09-30
BR112015011244A2 (pt) 2017-08-22
AU2018247243B2 (en) 2020-08-06
HK1215445A1 (zh) 2016-08-26
PT3660033T (pt) 2021-07-06
PL3660033T3 (pl) 2021-12-06
JP7441271B2 (ja) 2024-02-29
US20210032289A1 (en) 2021-02-04
WO2014078731A2 (fr) 2014-05-22
BR112015011244B1 (pt) 2022-08-09
RU2015119165A (ru) 2017-01-10
AU2020260435A1 (en) 2020-11-26
MX366404B (es) 2019-07-08
EP2920201A4 (fr) 2016-10-12
DK2920201T3 (da) 2020-04-14
LT3660033T (lt) 2021-07-12
US20160215020A1 (en) 2016-07-28
MX2015006154A (es) 2015-12-01
HUE055564T2 (hu) 2021-11-29
PT2920201T (pt) 2020-04-03
CA2891673A1 (fr) 2014-05-22
RS62243B9 (sr) 2022-11-30
IL266004A (en) 2019-06-30
JP2016505527A (ja) 2016-02-25
BR112015011244A8 (pt) 2018-01-23
AU2020260435B2 (en) 2022-11-17
EP2920201B1 (fr) 2020-01-08
CN110882376B (zh) 2023-10-20
US10035822B2 (en) 2018-07-31
JP2019070011A (ja) 2019-05-09
HK1217336A1 (zh) 2017-01-06
AU2013344462A1 (en) 2015-06-04
JP7093871B2 (ja) 2022-06-30
EP3660033B9 (fr) 2022-06-22
HUS2200026I1 (hu) 2022-06-28
HRP20211342T2 (hr) 2022-08-19
RU2705215C2 (ru) 2019-11-06
AU2023200929A1 (en) 2023-03-23
US10875893B2 (en) 2020-12-29
US20230091471A1 (en) 2023-03-23
IL238852A0 (en) 2015-06-30
DK3660033T3 (da) 2021-07-05
EP3929206A1 (fr) 2021-12-29
HRP20211342T1 (hr) 2021-11-26
DK3660033T5 (da) 2022-06-27
JP6873167B2 (ja) 2021-05-19
SI3660033T1 (sl) 2021-09-30
CN105051057B (zh) 2019-11-19
AU2018247243A1 (en) 2018-11-01
LTPA2022010I1 (fr) 2022-06-27
MX2019007709A (es) 2019-09-06
PL2920201T3 (pl) 2020-10-05
WO2014078731A3 (fr) 2014-07-31
FR22C1025I2 (fr) 2023-11-24
US20190194254A1 (en) 2019-06-27
JP2021107441A (ja) 2021-07-29
EP3660033B1 (fr) 2021-06-09
AU2013344462B2 (en) 2018-07-12
EP3660033A1 (fr) 2020-06-03
CN105051057A (zh) 2015-11-11

Similar Documents

Publication Publication Date Title
FR22C1025I2 (fr) Analogues de la compstatine à longue durée d'action et compositions et méthodes associées
EP2694095A4 (fr) Compositions comprenant des analogues du glucagon et leurs procédés de fabrication et d'utilisation
BR112015002512A2 (pt) limpador interdental
BR112014015681A2 (pt) análogos de glucagon
BR112013024076A2 (pt) análogos de glucagon
BR112013008601A2 (pt) formulações de emulsão de clevidipina contendo agentes antimicrobianos
BR112013008864A2 (pt) análogos d ciclosporina
CO6950470A2 (es) Formulaciones derivadas de decitabina
CO6940426A2 (es) Formulaciones farmacéuticas
FR2970177B1 (fr) Composition huileuse demaquillante
BR112014000773A2 (pt) composições de nicotinamida e uso terapêutico das mesmas
BR302012001298S1 (pt) Configuração aplicada edm equipamento médico
BR112013013550A2 (pt) membro de limpeza de material à base de elastômero (s) sobrerreticulado
DK2672817T3 (da) Forbedrede insekticide formuleringer
BR112014014774A2 (pt) combinação farmacêutica antineurítica e composições
ES1076265Y (es) Estructura de proteccion flexible mejorada
ES1072442Y (es) Peine de instrumentacion
CL2014001638A1 (es) Analogos de glucagon
CO7061032A2 (es) Análogos de glucagón
TH149282B (th) "องค์ประกอบสำหรับทำความสะอาด"
UA21928S (uk) Диван «баррі»
UA22515S (uk) Комбінезон дитячий
UA25728S (uk) Іграшка м'яконабивна «барашка»
TH1401001026B (th) องค์ประกอบทำความสะอาดผิวหนัง
FI20110208A0 (fi) Pelinappula